Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GTx, Inc. (GTXI), Intuitive Surgical, Inc. (ISRG): Three Horrendous Health-Care Stocks This Week

Page 1 of 2

A great week for the overall market didn’t trickle down to every stock. Here are three of the most horrendous health-care stocks this week.

Not so merry

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%.

As is often the case with small pharmaceutical companies, the culprit was the sale of new shares. On Wednesday, Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced a secondary offering to sell $50 million of new stock and plans to issue $75 million in senior notes maturing in 2020. Those numbers changed the following day, though, when the company announced that it would instead sell $25 million worth of shares and issue senior notes of $125 million.

The initial figure represented potential share dilution of around 10%, with the revised number half as large. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) plans to use the cash it raises primarily to fund development and to seek regulatory approval for its pancreatic cancer drug MM-398.

War of words

In the stock market, the old saying that “sticks and stones may break my bones, but words can never hurt me” doesn’t hold water. GTx, Inc. (NASDAQ:GTXI) investors experienced that reality firsthand this week, with shares dropping 15% from an online article published on Wednesday.

The Street’s Adam Feuerstein wrote about why a fund manager he knows is shorting GTx, Inc. (NASDAQ:GTXI) stock. This fund manager has accurately predicted negative clinical results for other biotech stocks recently. Investors quickly dumped shares of GTx, Inc. (NASDAQ:GTXI) in response to the article.

Intuitive Surgical, Inc. (NASDAQ:ISRG)

Wedbush responded to the article the next day, calling the criticisms of the phase 2 study of GTx, Inc. (NASDAQ:GTXI)’s Enobosarm “unfounded.” Wedbush analyst David Nierengarten said, “While we usually do not respond to a journalist repeating a short-seller’s thesis on a covered stock, the 25% drop intraday compels us to respond.” The firm reiterated its outperform rating on GTx, Inc. (NASDAQ:GTXI) and its price target of $9 per share.

Down on da Vinci
Long a health-care technology darling, the market doesn’t feel the love so much these days for Intuitive Surgical, Inc. (NASDAQ:ISRG). Shares fell 15% this week after the company announced disappointing preliminary second quarter numbers.

Sales for Intuitive Surgical, Inc. (NASDAQ:ISRG)’s da Vinci robotic surgical systems declined around 6% in the last quarter compared with a year ago. The company attributed the drop to “increased economic pressure on hospitals” and to “moderating growth” in benign gynecologic procedures. Intuitive Surgical, Inc. (NASDAQ:ISRG)’s statement that the slowdown in gynecologic procedure growth is due to “a trend by payers toward encouraging conservative management and treatment in outpatient settings” caused lots of eyebrows to rise.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!